Literature DB >> 11173875

High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease.

K Yamagata1, K Urakami, K Ikeda, Y Ji, Y Adachi, H Arai, H Sasaki, K Sato, K Nakashima.   

Abstract

In order to study progressive dementia in Alzheimer's disease (AD) patients, we analyzed the gene expression of apolipoprotein E (apoE). ApoE mRNA level in the brains of patients with AD was determined by the reverse transcriptase-polymerase chain reaction (RT-PCR) method. ApoE genotype and the promoter polymorphisms (-491A/T, Th1/E47cs) were determined by the PCR restriction fragment length polymorphism method. The apoE mRNA level was significantly higher in the AD group than the control group (p < 0.05). ApoE mRNA in the AD group with apoE epsilon 4 was also significantly higher than that in the control group with apoE epsilon 4 (p < 0.05). Our result did not indicate the possibility that the promoter polymorphisms modulate the apoE mRNA level. The higher level of apoE mRNA in AD with apoE epsilon4 may play an important role in the development of AD. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11173875     DOI: 10.1159/000051236

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  13 in total

1.  Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2012-01-30       Impact factor: 3.688

2.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

4.  AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.

Authors:  Ximena S Rossello; Urule Igbavboa; Gary A Weisman; Grace Y Sun; W Gibson Wood
Journal:  Brain Res       Date:  2012-01-18       Impact factor: 3.252

Review 5.  Natural Bioactive Products and Alzheimer's Disease Pathology: Lessons from Caenorhabditis elegans Transgenic Models.

Authors:  María D Navarro-Hortal; Jose M Romero-Márquez; Safa Osta; Victoria Jiménez-Trigo; Pedro Muñoz-Ollero; Alfonso Varela-López
Journal:  Diseases       Date:  2022-05-13

Review 6.  Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene.

Authors:  Debomoy K Lahiri
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure.

Authors:  Lynn M Bekris; Nichole M Galloway; Thomas J Montine; Gerard D Schellenberg; Chang-En Yu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

8.  C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease.

Authors:  Yiyuan Xia; Zhi-Hao Wang; Jichun Zhang; Xia Liu; Shan Ping Yu; Karen X Ye; Jian-Zhi Wang; Keqiang Ye; Xiao-Chuan Wang
Journal:  Mol Psychiatry       Date:  2020-12-18       Impact factor: 15.992

9.  Genetic studies in Alzheimer's disease.

Authors:  Ya-Ping Tang; Elliot S Gershon
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

10.  Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum.

Authors:  Eleanor S Drummond; Jill Muhling; Ralph N Martins; Linda K Wijaya; Erich M Ehlert; Alan R Harvey
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.